SCHEMBL13623014

SCHEMBL13623014

CC(C)(C)OC(=O)Nc1cccc(NS(=O)(=O)c2cccc(Nc3nc(Cl)ncc3Cl)c2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 4/20 0.49
SYK P43405 1/20 0.48
JAK1 P23458 2/20 0.45
HDAC1 Q13547 2/20 0.45
MEN1 O00255 2/20 0.44
HTT P42858 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPK1 P28482 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NR2F2 P24468 1/20 0.44
RAB9A P51151 1/20 0.44
MET P08581 2/20 0.43
STK17B O94768 1/20 0.43
STK17A Q9UEE5 1/20 0.43
BRD4 O60885 4/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KAT6A Q92794 1/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4180112 0.89 SYK (0.57) BTKSYKMETSTK17BSTK17A
SCHEMBL4348239 0.86 BTK (0.54) BTKJAK1HDAC1MEN1HTT
SCHEMBL24393225 0.85 SYK (0.48) BTKSYKJAK1HDAC1MEN1
SCHEMBL13623018 0.85 SYK (0.48) BTKSYKMETSTK17BSTK17A
SCHEMBL13622970 0.83 SYK (0.51) BTKSYKHDAC1MEN1KMT2A
SCHEMBL1025665 0.81 JAK1 (0.45) BTKJAK1HDAC1MEN1HTT
SCHEMBL13623118 0.81 AURKA (0.50) BTKSYKJAK1METSTK17B
SCHEMBL13623023 0.81 MET (0.49) BTKSYKMETSTK17BSTK17A
SCHEMBL13623131 0.80 SYK (0.50) BTKSYKMETSTK17BSTK17A
SCHEMBL9923768 0.80 SYK (0.56) BTKSYKMETSTK17BSTK17A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK BTK 20/4885SYK 46/4885JAK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.